Sign in Subscribe
Cancer research

COVID-19 mRNA Vaccines May Unlock Next-Generation Cancer Treatment

Strategic Insights

— 2 min read

A groundbreaking study published in the journal Nature suggests that COVID-19 mRNA vaccines could have a profound impact on cancer treatment, potentially leading to improved survival rates and extended benefits of immunotherapy for millions of patients. The research findings, led by pediatric oncologist Elias Sayour, reveal that patients who received either the Pfizer or Moderna mRNA-based COVID-19 vaccine within 100 days of starting immunotherapy were more than twice as likely to be alive after three years compared with those who didn't receive either vaccine.

Key Takeaways:

  • The study analyzed clinical outcomes for over 1,000 late-stage melanoma and lung cancer patients treated with immune checkpoint inhibitors, a common approach doctors use to train the immune system to kill cancer.
  • Patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy were more than twice as likely to be alive after three years compared with those who didn't receive the vaccine.
  • Patients with tumors that don't typically respond well to immunotherapy also saw very strong benefits, with nearly fivefold improvement in three-year overall survival.
  • The link between improved survival and receiving a COVID-19 mRNA vaccine remained strong even after controlling for factors like disease severity and co-occurring conditions.
  • The study found that COVID-19 mRNA vaccines act like an alarm, triggering the body's immune system to recognize and kill tumor cells and overcome the cancer's ability to turn off immune cells.
  • Researchers believe that mRNA vaccines that are not specific to a patient's cancer can "wake up the sleeping giant that is the immune system to fight cancer."
  • The study's findings suggest that mRNA vaccines may provide just the spark the immune system needs to turn "cold" tumors "hot."
  • The researchers are preparing to test this treatment strategy in patients with a nationwide clinical trial in people with lung cancer.
  • If validated, this approach could significantly extend the benefits of existing treatments to millions of patients.

Statistics:

  • 2.5 million lives saved globally during the pandemic through COVID-19 mRNA vaccines.
  • 1,000+ late-stage melanoma and lung cancer patients analyzed in the study.
  • 100 days: the timeframe within which patients must receive a COVID-19 mRNA vaccine for improved survival benefits.
  • 3 years: the time period over which patients were monitored for survival benefits.
  • 2x: the likelihood of patients who received a COVID-19 mRNA vaccine to be alive after three years compared with those who didn't receive the vaccine.
  • 5x: the improvement in three-year overall survival for patients with tumors that don't typically respond well to immunotherapy.

Sources:

  • Sayour et al., "mRNA vaccines can train the immune system to kill tumors," Nature (2023).
  • The Conversation -- USA (3) -- By Adam Grippin, Physician Scientist in Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center.
  • COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment -- new research -- https://theconversation.com/covid-19-mrna-vaccines-could-unlock-the-next-revolution-in-cancer-treatment-new-research-258992

Read more